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Abstract
Background: Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disease characterized by multiple
recurring clonal cytogenetic anomalies and is the most common leukemia in adults. Chromosomal abnormalities
associated with CLL include trisomy 12 and IGH;BCL3 rearrangement [t(14;19)(q32;q13)] that juxtaposes a proto-
oncogenic gene BCL3 and an immunoglobulin heavy chain, a translocation that may be associated with shorter
survival. In addition to the IGH;BCL3 rearrangement, other translocations involving 14q32 locus are involved in
various lymphoproliferative pathologies pointing toward the significance of IGH locus in oncogenic progression.
Significantly, in the majority of B-cell neoplasms that carry an IGH;BCL3 rearrangement, it is a sole translocation
involving an IGH locus.
Case Presentation: We report a patient who, in addition to trisomy 12, carried a rare double-hit translocation
characterized by the IGH;BCL3 translocation and an additional clonal IGH;BCL2 translocation involving IGH and
another proto-oncogene BCL2, t(14;18)(q32;q21), commonly found in follicular lymphoma. Further single nucleotide
polymorphism (SNP) array-based analysis detected a duplication of the 58.8 kb region at 19q13.32 adjacent to the
BCL3 translocation junction on chromosome 19q13. Interestingly, the duplicated region contained ERCC2 gene,
which encodes a DNA excision repair protein involved in the cancer-prone syndrome, xeroderma pigmentosum.
Conclusions: Taken together our findings indicate the existence of double-translocation driven oncogenic events
involving both IGH loci and proto-oncogenes BCL2 and BCL3. Importantly, the IGH;BCL3 translocation was characterized
by the duplication of the genomic region adjacent to BCL3, containing a major DNA repair factor, ERCC2.
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Background
Chronic lymphocytic leukemia (CLL) is a genetically
heterogeneous neoplasm characterized by the progres-
sive accumulation of B cells in bone marrow, lymph
nodes and blood. The progression of the disease is
highly variable, ranging from the indolent state to the
highly aggressive leukemia marked by short survival
times. Numerous chromosomal abnormalities have
been shown to contribute to CLL, including but not
limited to trisomy 12, loss of 11q22-q23 containing
the ATM gene, loss of 13q14.3 and 6q, loss of 17p13
containing TP53 gene, and others [1].
A specific translocation [t(14;19)(q32;q13)] which
juxtaposes the immunoglobulin heavy chain locus
(IGH) sequence (HUGO, 14q32.33) and the gene en-
coding an anti-apoptotic protein BCL3 resulting in
overexpression of BCL3 [2], is of a particular interest
because it does not occur frequently, and it is usually
associated with shorter survival [1]. In addition, this
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translocation as well as other translocations involv-
ing the IGH locus, although found in CLL, have been
also described in poorly clinicopathologically described
B cell lymphomas, categorized as atypical CLL [3].
Another translocation involving IGH locus and an anti-
apoptotic protein BCL2, t(14;18)(q32;q21), is consid-
ered a hallmark of aggressive lymphomas, such as
follicular lymphomas (FL) [4, 5] and diffuse large B-cell
lymphomas (DLBCL) [6–8].
We report a patient who was evaluated for leukocytosis
with lymphocytosis, and who was found to have a marked
bone marrow involvement by neoplastic lymphocytes
showing a B-cell line of differentiation as determined by
flow cytometry and immunohistochemistry. Morphologic-
ally, the lymphocytes were small to medium in size, and a
subset showed knobby cytoplasmic blebbing. Further
immunophenotypic studies ruled out involvement by typ-
ical CLL or mantle cell lymphoma in this patient,
highlighting an atypical characteristic of this malignancy.
Surprisingly, in addition to trisomy 12, which is com-
monly found in CLL, chromosome analysis at the hap-
loid band resolution 300-400 revealed the presence of
clones carrying a single t(14;19)(q32;q13) IGH;BCL3
translocation or both, t(14;19)(q32;q13) IGH;BCL3 and
t(14;18)(q32;q21) IGH;BCL2 translocations. Whereas
single translocation events involving IGH and BCL3 or
BCL2 loci can be detected in lymphoid cancers,
double-hit translocations involving both IGH;BCL2
and IGH;BCL3 rearrangements in the same patient are
exceptionally rare. Additionally, using SNP array ana-
lysis we detected a local microduplication event at the
BCL3 translocation junction on chromosome 19 in-
volving a DNA repair factor ERCC2. An additional file
describing experimental procedures is available (see
Additional file 1). However, due to the nature of the
SNP array platform we cannot exclude the possibility
that ERCC2 duplication occurred on the non-rearranged
chromosome 19. Given the absence of classical CLL and
mantle cell lymphoma immunophenotype, size and
morphology of the neoplastic lymphocytes, and the pres-
ence of B-cell lymphoproliferative genetic markers charac-
teristic of aggressive B-cell lymphomas, we favor the
diagnosis of an aggressive monoclonal B-cell lymphoma/
leukemia, likely B-prolymphocytic leukemia in this patient
driven by the IGH;BCL3 and IGH;BCL2 mediated
mechanisms.
Case presentation
Our patient was an 82-year-old African-American fe-
male who presented to her oncologist for leukocytosis.
Complete blood count (CBC) data showed a white
blood cell (WBC) count of 24.5 K/ MicroL with rela-
tive and absolute lymphocytosis of 70 % and 17.2K/
MicroL respectively. A bone marrow biopsy and
aspirate was performed and the specimen was sent
to the hematopathologist for evaluation. Flow cyto-
metric analysis showed 40 % monoclonal B-cells with
lambda light chain restriction of moderate intensity
with dim CD5 co-expression and the following
immunophenotype: CD10-, CD19+, CD20+, CD200-,
CD23 +/- (dim), FMC7 +/- (dim), CD38-, CD25-,
CD103- and CD11c-.
By histology the bone marrow showed marked involve-
ment by lymphocytes with interstitial pattern of distribu-
tion estimated at 80–90 % of the total marrow cellularity.
H&E staining, CD20 and Pax5 immunohistochemistry
confirmed the nature of the lymphocytes consistent with
B-cell line of differentiation (Fig. 1a and b and data not
shown). No lymphoid aggregate formation was seen. Mor-
phologically the lymphocytes were small to medium in
size and showed clumped nuclear chromatin with small
but conspicuous nucleoli and no morphologic features
suggestive of involvement by DLBCL, Burkitt lymphoma
or other high-grade aggressive B-cell lymphomas.
By immunohistochemistry the B-cells were negative
for Cyclin-D1 and, additionally, they were negative for
Sox-11, arguing against the diagnosis of mantle cell
lymphoma or Cyclin-D1 negative mantle cell lymphoma,
respectively. Evaluation of the aspirate smear showed the
lymphocytes with occasional small knobby cytoplasmic
blebbing but no discernible villous hairy projections.
Overall, based on the immunophenotypic finding by
flow cytometric analysis, it is unlikely that this lymphoma
represents typical CLL, since it not only expresses mono-
clonal light chain with moderate intensity, it also shows
weak CD23 expression and is negative for CD200. The
possibility of mantle cell lymphoma and Cyclin D-1 nega-
tive mantle cell lymphoma was considered and further
evaluated but ruled out by negative staining with Cyclin
D1 and Sox-11 immunohistochemistry respectively. Given
the morphologic observation of knobby cytoplasmic
blebbing, the diagnosis of B-PLL (B- prolymphocytic
leukemia) was considered a strong possibility.
Cytogenetic studies of bone marrow preparations from
this patient revealed two related abnormal clones in
eight of twenty-two metaphase spreads examined. The
first clone (stemline [sl]), six cells, contained a transloca-
tion between the long (q) arm of chromosomes 14 and
19 (Fig. 2a, arrows), and gain of one copy of chromo-
some 12 (underlined). The second clone, a composite of
two cells, was a doubling of the stemline clone (the first
clone) with two copies of an additional translocation be-
tween 14q and 18q (Fig. 3a, red arrows, six copies of
chromosome 12 are underlined). The remaining four-
teen cells contained a normal karyotype. Additionally,
FISH studies using BCL3 and IGH break-apart probes
confirmed BCL3 and IGH translocations in the first
clone (Fig. 2b and c, arrows). With respect to the second
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Fig. 1 a H&E staining of the bone marrow showing marked interstitial involvement by medium sized cells with small but conspicuous
nucleoli. b CD20 immunohistochemistry highlights marked involvement of the bone marrow by abnormal B-cells
Fig. 2 a Karyotype of the first clone. The first clone (stemline [sl]), six cells, contained a translocation between the long (q) arms of chromosomes
14 and 19 (arrows), and gain of one copy of chromosome 12 (underlined). b BCL3 break-apart FISH probe (green/red) indicates rearrangement of
a BCL3 locus in the first clone (arrows). Normal FISH signal is shown on the right side of the panel for comparison. c IGH break-apart FISH probe
(green/red) indicates rearrangement of an IGH locus in the first clone (arrows). Normal FISH signal is shown on the right side of the panel
for comparison
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clone, IGH;BCL2 dual-fusion probe picked up eight sig-
nals for IGH (Fig. 3b, black and white IGH image) which,
in combination with karyotype data, was indicative of
the presence of eight IGH derivative translocation prod-
ucts. This suggests that all IGH loci are rearranged in
the second clone in addition to the near duplication of
the chromosome content. BCL2 probe picked up six
BCL2 signals (Fig. 3b, black and white BCL2 image) indi-
cating on the presence of four translocated BCL2 loci
and two intact BCL2 loci from the non-translocated
chromosome 18. Importantly, IGH and BCL2 signals
formed four fusions (Fig. 3b, “merge” panel, arrows) con-
firming two derivative IGH;BCL2 loci on chromosomes
14 and chromosome 18. In addition, IGH break-apart
probe confirmed the presence of four translocated IGH
loci (Fig. 3b, right panel, four red and four green
signals). In summary, first clone was characterized by
the IGH;BCL3 translocation event resulting in derivative
chromosomes, 14 and 19 (Fig. 4a) and second clone was
characterized by the presence of IGH;BCL2 translocation
in addition to IGH;BCL3 translocation and near tetra-
ploid chromosome content resulting in four derivative
chromosomes 14 and two derivative chromosomes 18
and 19 (Fig. 4b).








Fig. 3 a Representative karyotype of the second clone. The second clone, a composite of two cells, was a doubling of the stemline clone (the
first clone) with two copies of a translocation between 14q and 18q (IGH;BCL2, red arrows), in addition to a 14q and 19q translocation (IGH;BCL3,
white arrows). Six copies of chromosome 12 are underlined. b FISH analysis of the second clone using dual fusion IGH;BCL2 probe (green/red).
Black and white image for IGH signal shows 8 loci indicating that all IGH sequences are rearranged and present on derivative chromosomes 14,
18, and 19. Black and white image for BCL2 signal shows 6 loci which represent two intact and two derivative chromosomes 18, and two
derivative chromosomes 14. Merged image shows green IGH signals and red BCL2 signals which overlap in four loci, arrows (two copies of
derivative chromosome 14 and two copies of derivative chromosome 18). Right panel, IGH break-apart probe (green/red) signal showing four
green and four red foci indicative of the presence of four rearranged IGH loci
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Further studies using single nucleotide polymorphism
arrays on the patient’s DNA sample detected the pres-
ence of an extra chromosome 12, confirming our
karyotype analysis (Fig. 5a). Interestingly, we also de-
tected a microduplication event at the cytogenetically
defined BCL3 translocation junction (19q13.1) con-
taining a major nucleotide excision repair gene ERC
C2 (ISCN arr[hg19](12)X3,19q13.32(45,835,983-45,
894,768)x3), (Fig. 5b-d). Polymorphisms in this gene
are associated with xeroderma pigmentosum (XP), XP
associated with Cockayne syndrome (XP/CS), and tri-
chothiodystrophy (TTD) [9]. However, we do not ex-
clude the possibility that ERCC2 duplication occurred
on the intact chromosome 19.
Conclusions
In this report we describe a case of a monoclonal B-cell
lymphoma/leukemia with extensive bone marrow involve-
ment and CLL-like immunophenotype showing CD5
expression by flow cytometric analysis and furthermore dis-
playing a double translocation event between IGH loci and
both BCL3 and BCL2 gene loci. Additionally, we detected a
microduplication event in the genomic locus adjacent to
BCL3 gene involving a nucleotide excision repair protein
ERCC2. Our karyotype analysis identified two abnormal
clones in this patient. The first clone contained, in addition
to trisomy 12, a single cytogenetically defined translocation
t(14;19)(q32;q13) involving IGH;BCL3 loci. The second
clone represented a near duplication of the chromosome
content of the first clone and the presence of two copies of
an additional translocation involving IGH locus and BCL2
gene t(14;18)(q32;q21). Therefore, all IGH loci located on
the chromosome 14 were rearranged in the second clone
which was confirmed by our FISH studies.
These results are consistent with a neoplastic process in
this patient’s bone marrow specimen. Importantly, the
translocation t(14;19)(q32;q13) involving IGH and BCL3
loci, which results in altered BCL3 expression, has been
described in aggressive forms of lymphomas and atypical
CLLs [3, 10]. The translocation t(14;18)(q32;q21) is a re-
curring abnormality in B-cell lymphomas. This transloca-
tion places the oncogene BCL2 on 18q21 within the
immunoglobulin heavy chain locus on 14q32 and there-
fore deregulates the BCL2 function. Juxtaposition of both
Fig. 4 Schematic representation of the rearrangements described in clone 1 and clone 2. Chromosomes involved in rearrangements are shown
on the right. a Rearrangements in clone 1 involving IGH (14q32) and BCL3 (19q13.1) which results in two derivative chromosomes (der(19) and
der(14). Rearranged chromosomes 14 and 19 are indicated by an arrow on the right. b Rearrangements in clone 2 which includes chromosome
duplication event and IGH (14q32) and BCL2 (18q21) translocation in addition to IGH;BCL3 rearrangements. Therefore clone 2 contains 8 derivative
chromosomes (a pair of each der(19), der(18), der(14)t(14;19), and der(14)t(14;18)). Rearranged chromosomes 18 and 19 are indicated by the
arrows on the right
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BCL3 and BCL2 genes next to the active IGH locus leads
to their altered expression, decreased apoptosis, and
leukemia progression [10, 11]. Concurrent rearrangements
of BCL2(18q21) and BCL3(19q13) have been reported in
atypical chronic lymphocytic leukemia at Richter's trans-
formation [12]. Both BCL3 and BCL2 are proto-
oncogenes, however mechanistically, BCL2 functions as a
key regulator of apoptosis through the mitochondrial
pathways [11], whereas BCL3 is a predominantly nuclear
protein recruited to the NFκB-responsive promoters
where it regulates apoptotic program [13], suggesting that
rearrangements of BCL2 and BCL3 may differentially
modulate leukemic progression through distinct molecu-
lar pathways. The appearance of the IGH;BCL3 clone
followed by the genome near duplication event and the
appearance of the second clone containing both
IGH;BCL3 and IGH;BCL2 rearrangements in our patient
might, therefore, have an additive effect on the develop-
ment of this neoplasm.
ERCC2 duplication in this patient is an intriguing find-
ing, because of the role of ERCC2 in DNA nucleotide exci-
sion repair process. Specific ERCC2 polymorphisms are
implicated in susceptibility to melanoma [14] as well as
triple negative breast cancer [15]. However, according to
the Database of Genomic Variants (http://dgv.tcag.ca/dgv/
app/home), duplications of ERCC2 genomic region are
also found in healthy individuals. Therefore, the signifi-
cance of ERCC2 duplication in context of IGH;BCL3 and
Fig. 5 Single Nucleotide Polymorphism (SNP) array analysis. a Confirmation of an extra copy of chromosome 12. In the Log R ratio panel (left)
chromosomal boundaries between the q terminal of chromosome 11, chromosome 12, and the p terminal of chromosome 13 are demarcated
by lines. The expanded chromosome 12 view (right), shows an isolated view of chromosome 12 (B-Allele frequency). b Microduplication of the
genomic region containing ERCC2 gene. c Genomic mapping of ERCC2 gene located in the 19q13.32 cytogenetic band, proximal to the BCL3
gene locus (19q13.31). d Placement of the ERCC2 gene relative to the hypothesized IGH;BCL3 rearrangement junction depicted in the schematics
(the possibility exists that ERCC2 duplication occurred on the non-translocated chromosome 19 as stated in text)
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IGH;BCL2 rearrangements requires further investigation.
Additionally, the existence of the microduplication event
at the major translocation junction supports the previ-
ously reported genomic instability events at the transloca-
tion breakpoints and emphasizes the significance of the
molecular analysis of sequences adjacent to the cytogenet-
ically defined translocation junctions including balanced
rearrangements [16].
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